Wegovy® pen and pill: the evidence, the risks and how the membership works

Wegovy® is Novo Nordisk’s FDA-approved semaglutide for chronic weight management, taken as a weekly pen or a daily tablet. It is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight. Through VevaMD a board-certified physician decides whether it fits you; you pay a VevaMD membership, and Novo Nordisk for the medication.

FDA-approved brandWeekly pen or daily tablet

See if Wegovy fits me →

A board-certified, US-licensed physician reviews every intake.

What Wegovy costs at VevaMD

  • VevaMD membership: $149 a month, or $237 every 3 months ($79/mo. Save $210 versus paying monthly.). Two charges. This price is the VevaMD membership for physician review. You pay the manufacturer directly for the medication.
  • Wegovy pen: $199 for each of the first two monthly fills of 0.25 mg and 0.5 mg through December 31, 2026, then $349 a month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, paid to Novo Nordisk. In total $348–$498 a month ($149 membership + $199–$349/mo to Novo Nordisk).
  • Wegovy pill: $149 a month at 1.5 mg, $199 a month at 4 mg, and $299 a month at 9 mg and 25 mg, paid to Novo Nordisk. In total $298–$448 a month ($149 membership + $149–$299/mo to Novo Nordisk).
  • After a physician prescribes, create your NovoCare account and pay the pharmacy there. VevaMD does not create that account. The published self-pay price applies when they fill it under their terms.
  • Full refund of your first membership payment if nothing is prescribed. The membership does not change with your dose.

What Wegovy is

Wegovy® is semaglutide, a GLP-1 receptor agonist, made by Novo Nordisk and approved by the FDA. It comes two ways. The pen is a weekly injection under the skin. The tablet is taken once each morning, and it is approved for weight reduction and heart-risk reduction in adults [1]. Both are used with a reduced-calorie diet and more physical activity.

Its approvals go beyond weight. The label covers lowering the risk of major cardiovascular events in adults with established heart disease and obesity or overweight, long-term weight reduction in adults and in adolescents 12 and older with obesity, and, for the injection, a form of fatty liver disease called MASH with moderate to advanced scarring [1]. The FDA called it the first weight medicine also approved to help prevent heart attacks and strokes in that group [2].

How Wegovy works

Semaglutide is built to closely resemble GLP-1, the fullness hormone your gut releases after a meal; the label puts the match at 94% of its sequence. It acts on GLP-1 receptors in the brain areas that regulate appetite, lowers calorie intake and slows stomach emptying, and the weight it lowers is more fat than lean mass [1]. Your physician pairs it with eating and activity changes, because medicines like it are adjuncts to lifestyle change, not replacements for it [3].

Pen or pill: the practical differences

  • The pen is a weekly injection under the skin of the stomach, thigh or upper arm, from a prefilled pen. A pen belongs to one person and is never shared, even with a new needle [1].
  • The tablet is swallowed whole each morning on an empty stomach with a small sip of water, up to 4 ounces, followed by at least 30 minutes before eating, drinking or taking other pills [1].
  • Switching between the two is possible; the label sets out how a physician moves someone from one form to the other [1].
  • Price: the VevaMD membership is the same for the pen and the tablet, while the Novo Nordisk self-pay price differs by form and strength [4].

How you get Wegovy through VevaMD

Wegovy through VevaMD is two charges, and we say so up front. The first is the VevaMD membership, $149/mo or less if you prepay a quarter: it covers your board-certified physician, the prescription and your ongoing care. The second is the medication itself, which you pay to Novo Nordisk at its published self-pay price through NovoCare® Pharmacy [4]. VevaMD does not charge you for the medication, and the full numbers are in the price section above.

  1. Answer the private intake. A physician licensed in your state reviews it and may message you or ask for labs.
  2. If Wegovy® fits you, your physician chooses the pen or the tablet and sends the prescription to NovoCare® Pharmacy.
  3. You create your NovoCare® account and pay Novo Nordisk there; it ships the medication to you.
  4. Your physician stays with you through each step-up and the check-ins that follow, under the same membership.

Who Wegovy is for

Approved for

  • Adults with obesity (BMI 30 or more), or with overweight (BMI 27 or more) and at least one weight-related condition [1]
  • Adults with established heart disease, such as a past heart attack or stroke, and obesity or overweight, to lower the risk of further events [1]
  • People who prefer a pill to an injection: the tablet is approved for adults on the same terms [1]

Not for

  • Anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2 [1]
  • Anyone with a serious allergy to semaglutide or to anything in the pen or tablet [1]
  • Anyone pregnant or planning a pregnancy in the next 2 months, and anyone breastfeeding while on the tablet [1]
  • Anyone using another semaglutide product or another GLP-1 medicine [1]

What the trials found

Weight, injection. In the trial known as STEP 1, 1,961 adults with obesity or overweight but without diabetes took Wegovy or a placebo for 68 weeks, alongside lifestyle support. Average weight change was -14.9% on semaglutide and -2.4% on placebo; 86.4% on semaglutide lost at least 5% of their weight, against 31.5% on placebo, and 50.5% lost at least 15% [5]. Across the label’s weight trials, 71% of participants were women and the average age was 48 [1].

Weight, tablet. In the OASIS 4 study, 307 adults took the Wegovy tablet or a placebo every day for 64 weeks. Average weight change was -13.6% on the tablet and -2.2% on placebo. Stomach side effects were more common on the tablet: 74.0% against 42.2% [6].

Heart. The SELECT study enrolled 17,604 adults aged 45 and older with heart disease and a BMI of 27 or more, without diabetes, and followed them for about 40 months. A heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide and 8.0% on placebo, a 20% lower risk [7]. More people stopped the drug because of side effects on semaglutide (16.6%) than on placebo (8.2%) [7].

What to expect over time

  1. Months 1 to 4The pen and the tablet both start low and step up, about monthly, to the maintenance amount; your physician can hold a step if side effects need time to settle [1].
  2. Month 4 onwardThe maintenance phase, with regular check-ins. In STEP 1 the most common side effects, nausea and diarrhea, were typically mild to moderate and eased with time [5].
  3. If you stopIn the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and the improvements in blood pressure and cholesterol largely faded [8]. Wegovy is meant as long-term treatment.

Side effects and the boxed warning

Most common side effects with the Wegovy® pen in the weight trials (adults, percent of people)
Side effectWegovy® penPlacebo
Nausea44% [1]16%
Diarrhea30% [1]16%
Vomiting24% [1]6%
Constipation24% [1]11%
Stomach pain20% [1]10%
Headache14% [1]10%

Stomach side effects were mostly mild to moderate and eased with time; 4.5% of people in STEP 1 stopped semaglutide because of them [5]. Less common but serious risks on the label include pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach side effects, allergic reactions, a faster heart rate, low blood sugar with insulin or a sulfonylurea, diabetic eye complications, and aspiration under anesthesia [1]. The suicidal thoughts warning was removed from the label in February 2026 [1].

Getting the most from it. Wegovy® works alongside habits, not instead of them. NIDDK points to federal guidance of at least 150 minutes a week of moderate activity [9], and the Menopause Society advises strength training on two days of the week, with enough protein, to protect muscle in midlife [10]. Your physician can build both into your plan.

Wegovy compared with the other options

The same intake can lead to any of four options, and your physician recommends the one that fits. Compounded semaglutide is a compounded product prepared by a pharmacy: it is not FDA-approved and it is not Wegovy®. Zepbound® is the other FDA-approved brand through a membership.

The four GLP-1 options at VevaMD
FDA statusHow it is takenHow you pay at VevaMDMain trade-offs
Compounded semaglutideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $199/mo: physician, medication and shipping. No membership feeThe lowest monthly price, the same at every dose; you draw each dose with a syringe
Compounded tirzepatideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $299/mo: physician, medication and shipping. No membership feeActs on two gut-hormone receptors, GLP-1 and GIP; the same price at every dose; you draw each dose with a syringe
Wegovy®FDA-approved brandWeekly prefilled pen, or a daily tabletA $149/mo VevaMD membership, plus the self-pay price paid to Novo Nordisk ($348–$498/mo in total for the pen)Approved for weight and to lower heart risk in adults with heart disease; pen or pill; two separate charges
Zepbound®FDA-approved brandWeekly prefilled penA $149/mo VevaMD membership, plus the self-pay price paid to Eli Lilly ($448–$598/mo in total)Approved for weight and for moderate to severe sleep apnea with obesity; prefilled pen; two separate charges

Weight gain in perimenopause and menopause

Women aged 50 to 64 are the most represented age group among US GLP-1 users, and midlife weight gain is a common reason: aging drives most of it, and menopause adds fat gain and redistribution [11]. In a study presented at the Menopause Society’s 2026 meeting, among nearly 2,400 midlife women taking semaglutide, those who also used hormone therapy lost more weight, and kept it off better, than those who did not. It was an observational study, so it cannot prove hormone therapy caused the difference [11].

Common questions

Do I pay VevaMD for the Wegovy medication?

No. You pay VevaMD a membership for your physician and ongoing care, and you pay Novo Nordisk directly for Wegovy at its self-pay price through NovoCare Pharmacy. VevaMD does not charge you for the medication.

Should I take the Wegovy pen or the Wegovy pill?

Both are FDA-approved semaglutide for weight reduction. The pen is a weekly injection; the tablet is taken each morning with a little water on an empty stomach. Your physician weighs your history and preference, and the membership price is the same either way.

Is Wegovy approved for heart disease?

The FDA approved Wegovy in March 2024 to lower the risk of cardiovascular death, heart attack and stroke in adults with established heart disease and either obesity or overweight. That approval is for that group specifically.

Does the Wegovy membership cost more at higher doses?

No. The VevaMD membership stays the same when your dose changes. The Novo Nordisk self-pay price is set by Novo Nordisk and can differ by strength.

Can I get Ozempic for weight loss through VevaMD?

Not right now. Ozempic is not offered for weight loss until NovoCare confirms its self-pay price and who can use it. Wegovy, the semaglutide pen and pill approved for weight management, is available.

Does VevaMD bill my insurance for Wegovy?

No. VevaMD does not bill insurance. The membership and the NovoCare self-pay price are paid directly; VevaMD provides itemized receipts for the membership.

A physician decides what fits you

See if Wegovy fits me →

One private online intake covers every GLP-1 option. You see your price before you pay, and your first payment is refunded in full if nothing is prescribed.

Sources

  1. WEGOVY® (semaglutide) injection and WEGOVY® (semaglutide) tablets prescribing information. Novo Nordisk. DailyMed, revised June 2026. Checked October 28, 2026.
  2. FDA. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. News release, March 8, 2024. Checked October 28, 2026.
  3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. Checked October 28, 2026.
  4. Novo Nordisk. NovoCare® Pharmacy: self-pay prices for Wegovy® and Ozempic®. Checked October 28, 2026.
  5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. Checked October 28, 2026.
  6. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. Checked October 28, 2026.
  7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. Checked October 28, 2026.
  8. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. Checked October 28, 2026.
  9. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription medications to treat overweight and obesity. Checked October 28, 2026.
  10. The Menopause Society. MenoNote: Midlife weight gain. Checked October 28, 2026.
  11. The Menopause Society. Hormone therapy may increase weight loss effectiveness of GLP-1s. News release, October 20, 2026. Checked October 28, 2026.

Last updated . Content standards

Clinical care is provided by board-certified, US-licensed physicians. VevaMD Inc is a technology and marketing storefront only — not a medical provider or a pharmacy. Medications are dispensed by licensed U.S. partner pharmacies after a valid prescription. Wegovy®, Ozempic®, Zepbound® and Mounjaro® are trademarks of their owners. VevaMD is not affiliated with Novo Nordisk or Eli Lilly. This page is general information, not medical advice. A prescription is not guaranteed, and outcomes differ from person to person. Report a side effect to FDA MedWatch.